glp-1/gip/glucagon triple agonist LY3437943, a novel glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Dual and Triple Gut Peptide

If Novo can combine oral convenience with amylin-based efficacy, it could create a differentiated next-generation product that sits between todays oral GLP-1 drugs and tomorrows combination therapies

This pathway also downregulates Wilms tumor protein expression, a key factor for podocyte protection, contributing to proteinuria [63]

Micronutrient supplementation may be beneficial, though ideally guided by laboratory assessment rather than empiric supplementation

Fourth, some behavioral paradigms, such as CPP and locomotor sensitization, rely heavily on associative learning and may not fully capture compulsive aspects of drug seeking seen in clinical populations

[DOI] [PMC free article] [PubMed] [Google Scholar] 43.Zhu C., Li H., Kong X., Wang Y., Sun T., Wang F